source
- Dimerix acquires Mission's phase-2 ready AKI drug in $292 million dealDimerix announced it has acquired the acute kidney injury candidate MTX652 from Mission Therapeutics in a deal valued at up to $292 million, including a $5 million upfront payment. Mission had com…
- Mid-size biotech firms urge White House to scrap CMS GLOBE and GUARD pricing proposalsA group of midsized biotechnology companies met with officials from the White House and the Department of Health and Human Services this week. The companies presented a coordinated case to senior p…